Efficacy Of Prochlorperazine Research Articles

To compare the effect of cyclizine, prochlorperazine and ondansetron in inhibiting postoperative nausea and vomiting following laparoscopic cholecystectomy

Objective: To determine the efficacy of prochlorperazine, cyclizine and ondansetron in patients following laparoscopic cholecystectomy, in terms of prevention of vomiting and nausea. Study Type: Randomized Control Trial. Duration and Location of Study: Anaesthesia department of the Bahawal Victoria Hospital, Bahawalpur over a period of January, 2018 to January, 2019. Methodology: Total of 324 patients divided into Group P, group O and group C received prochlorperazine (10mg), ondansetron (4mg) and cyclizine (50mg) respectively. Every patient was asked to tell when he/she is feeling nauseous, vomited and used additional antiemetic drugs. Descriptive data was compared by applying ANOVA test and Chi-square or Fischer’s exact test was applied on nominal data. Computer software SPSS version 23 was used to statistically analyze the data. P ≤0.05 was taken as significant., Results: Although occurrence of side effects was slightly higher in group-P, but all the groups were not statistically diffrent (p-value 0.581, 0.500 and 0.544 for headache, dizziness and sedation, respectively). Nausea and vomiting was observed in 4.6% in group-O patients, 5.5% in group-C patients and 8.3% in group-P patients, difference being statistically insignificant (p=0.500). , Conclusion: From the results of this study it can be concluded that all the three drugs i.e. cyclizine, ondansetron and prochlorperazine are equally effective and there is no statistically significant difference in terms of prevention of vomiting and nausea in patients undergoing cholecystectomy through laparoscope. Keywords: Ondansetron, Cyclizine, Prochlorperazine, postoperative nausea and vomiting DOI : 10.7176/JMPB/52-16

Compare the Efficacy of Prochlorperazine and Granisetron in Patients Undergoing Total Abdominal Hysterectomy

Compare the Efficacy of Prochlorperazine and Granisetron in Patients Undergoing Total Abdominal Hysterectomy

Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy

The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy. Cancer patients (n = 232) receiving moderately high to highly emetogenic chemotherapy were randomized to 1 of 3 treatments: 15 mg prochlorperazine spansules twice daily; 8 mg ondansetron tablets twice daily; or 8 mg dexamethasone tablets twice daily on days 2 through 5. All patients received 24 mg ondansetron and 20 mg dexamethasone orally before chemotherapy. Daily assessment (days 1 through 5) included the number of episodes of retching and vomiting, severity of nausea, restlessness, difficulty concentrating and fatigue, treatment satisfaction, and overall quality of life (measured using a 10-cm VAS). The Functional Living Index-Emesis (FLIE) was completed on day 5. Other side effects attributed to antiemetic therapy were recorded daily. For acute CINV, total control, defined as no vomiting, retching, nausea <1 cm on a 10-cm visual analog scale, and no administration of rescue medications, was achieved in 78% in the overall group and was not significantly different in the patients randomized to the 3 treatment arms for delayed CINV. Delayed CINV was reported by 43% to 57% of patients, with the highest incidence reported on day 3. For delayed CINV, patients receiving prochlorperazine reported the lowest average nausea score on days 2 to 5, whereas patients receiving ondansetron reported the highest nausea score (P = 0.05). No statistically significant differences in CINV or side effects of antiemetic therapy were noted between treatment groups on days 2 to 5. For patients similar to those included in this study, there does not appear to be a clinically important difference in efficacy, adverse effects, or treatment satisfaction among dexamethasone, prochlorperazine, and ondansetron in the doses used in these delayed CINV regimens on days 2 to 5 in this study.

Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: A prospective, randomized, controlled trial

Study Objective: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion. Methods: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital. Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion. Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group). The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration. Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale. The intensity of headache and nausea was measured with a 100-mm visual analog scale. Results: One hundred patients were enrolled. One study participant was excluded after protocol violation. Seventy-three percent (73/99) of the study participants were treated for headache and 70% (70/99) for nausea. In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Δ=–6.7%; 95% confidence interval [CI] –24.6% to 11.2%). The difference between the bolus and infusion groups in the percentage of participants who saw a 50% reduction in their headache intensity within 30 minutes was 11.8% (95% CI –9.6% to 33.3%). The difference in the percentage of patients with a 50% reduction in their nausea was 12.6% (95% CI –4.6% to 29.8%). Conclusion: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected. The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made. [Collins RW, Jones JB, Walthall JDH, Chisholm CD, Giles BK, Brizendine EJ, Cordell WH. Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial. Ann Emerg Med. November 2001;38:491-496.]